Application of Tivantinib for Hepatocellular Carcinoma: A Meta-Analysis Study

Abstract

Objectives. The efficacy of tivantinib may have some potential in treating MET-high hepatocellular carcinoma, and we aim to compare tivantinib with placebo for the treatment of MET-high hepatocellular carcinoma. Methods. Several databases including PubMed, Cochrane Library, Web of Science, EBSCO, and EMbase have been systematically searched through March 2022, and we included studies regarding the treatment of MET-high hepatocellular carcinoma by using tivantinib versus placebo. Results. We finally include three RCTs. In comparison with placebo for MET-high hepatocellular carcinoma, tivantinib reveals no significant influence on overall survival ( $P=0.21$ ), progression-free survival ( $P=0.13$ ), time to progression ( $P=0.38$ ), or grade ≥3 anemia ( $P=0.50$ ) but increases the incidence of grade ≥3 neutropenia ( $P=0.04$ ). Conclusions. Tivantinib may provide no additional benefits for MET-high hepatocellular carcinoma.